Table 5
Open in new tab

Published pharmacodynamic studies on switching

StudyYearPatients includedType of switchResults
Payne et al.192200839 healthy subjectsClopidogrel/prasugrelSwitching to prasugrel (with LD or MD) was well tolerated and resulted into greater platelet inhibition compared with clopidogrel MD.
SWAP1932010100 ACS patientsClopidogrel/prasugrelIn patients receiving clopidogrel during ACS, switching to prasugrel was associated with an additional reduction of platelet function after 1 week with MD or <2 h with LD administration.
Capranzano et al.194201120 patients aged ≥75 yearsClopidogrel/prasugrelSwitching to prasugrel 5 mg MD in elderly patients who were poor responders to clopidogrel was associated with greater platelet inhibition
TRIGGER-PCI1952012212 stable patientsClopidogrel/prasugrel treated with DESIn patients who were poor responders to clopidogrel, prasugrel LD produced an antiplatelet effect with a good safety profile.
Lhermusier et al.196201280 ACS patientsClopidogrel/prasugrelIn patients who were poor responders to clopidogrel, prasugrel LD was associated with an effective antiplatelet effect.
Nuhrenberg et al.197201347 STEMI patientsClopidogrel/prasugrelPrasugrel LD produced optimal antiplatelet effect, independently of clopidogrel pre-loading.
Cuisset et al.1982013107 ACS patientsClopidogrel/prasugrelPrasugrel LD was associated with a better antiplatelet effect in diabetic patients with a fairly good safety profile (10% of major bleeding events).
TRIPLET1992013282 ACS patientsClopidogrel/prasugrelPlatelet reactivity obtained with prasugrel LD (60 mg) after 600 mg clopidogrel was not different from that obtained with prasugrel LD (60 mg) alone.
StudyYearPatients includedType of switchResults
Payne et al.192200839 healthy subjectsClopidogrel/prasugrelSwitching to prasugrel (with LD or MD) was well tolerated and resulted into greater platelet inhibition compared with clopidogrel MD.
SWAP1932010100 ACS patientsClopidogrel/prasugrelIn patients receiving clopidogrel during ACS, switching to prasugrel was associated with an additional reduction of platelet function after 1 week with MD or <2 h with LD administration.
Capranzano et al.194201120 patients aged ≥75 yearsClopidogrel/prasugrelSwitching to prasugrel 5 mg MD in elderly patients who were poor responders to clopidogrel was associated with greater platelet inhibition
TRIGGER-PCI1952012212 stable patientsClopidogrel/prasugrel treated with DESIn patients who were poor responders to clopidogrel, prasugrel LD produced an antiplatelet effect with a good safety profile.
Lhermusier et al.196201280 ACS patientsClopidogrel/prasugrelIn patients who were poor responders to clopidogrel, prasugrel LD was associated with an effective antiplatelet effect.
Nuhrenberg et al.197201347 STEMI patientsClopidogrel/prasugrelPrasugrel LD produced optimal antiplatelet effect, independently of clopidogrel pre-loading.
Cuisset et al.1982013107 ACS patientsClopidogrel/prasugrelPrasugrel LD was associated with a better antiplatelet effect in diabetic patients with a fairly good safety profile (10% of major bleeding events).
TRIPLET1992013282 ACS patientsClopidogrel/prasugrelPlatelet reactivity obtained with prasugrel LD (60 mg) after 600 mg clopidogrel was not different from that obtained with prasugrel LD (60 mg) alone.

DES, drug-eluting stent; LD, loading dose; MD, maintenance dose; ACS, acute coronary syndrome; STEMI, ST elevation myocardial infarction.

Table 5
Open in new tab

Published pharmacodynamic studies on switching

StudyYearPatients includedType of switchResults
Payne et al.192200839 healthy subjectsClopidogrel/prasugrelSwitching to prasugrel (with LD or MD) was well tolerated and resulted into greater platelet inhibition compared with clopidogrel MD.
SWAP1932010100 ACS patientsClopidogrel/prasugrelIn patients receiving clopidogrel during ACS, switching to prasugrel was associated with an additional reduction of platelet function after 1 week with MD or <2 h with LD administration.
Capranzano et al.194201120 patients aged ≥75 yearsClopidogrel/prasugrelSwitching to prasugrel 5 mg MD in elderly patients who were poor responders to clopidogrel was associated with greater platelet inhibition
TRIGGER-PCI1952012212 stable patientsClopidogrel/prasugrel treated with DESIn patients who were poor responders to clopidogrel, prasugrel LD produced an antiplatelet effect with a good safety profile.
Lhermusier et al.196201280 ACS patientsClopidogrel/prasugrelIn patients who were poor responders to clopidogrel, prasugrel LD was associated with an effective antiplatelet effect.
Nuhrenberg et al.197201347 STEMI patientsClopidogrel/prasugrelPrasugrel LD produced optimal antiplatelet effect, independently of clopidogrel pre-loading.
Cuisset et al.1982013107 ACS patientsClopidogrel/prasugrelPrasugrel LD was associated with a better antiplatelet effect in diabetic patients with a fairly good safety profile (10% of major bleeding events).
TRIPLET1992013282 ACS patientsClopidogrel/prasugrelPlatelet reactivity obtained with prasugrel LD (60 mg) after 600 mg clopidogrel was not different from that obtained with prasugrel LD (60 mg) alone.
StudyYearPatients includedType of switchResults
Payne et al.192200839 healthy subjectsClopidogrel/prasugrelSwitching to prasugrel (with LD or MD) was well tolerated and resulted into greater platelet inhibition compared with clopidogrel MD.
SWAP1932010100 ACS patientsClopidogrel/prasugrelIn patients receiving clopidogrel during ACS, switching to prasugrel was associated with an additional reduction of platelet function after 1 week with MD or <2 h with LD administration.
Capranzano et al.194201120 patients aged ≥75 yearsClopidogrel/prasugrelSwitching to prasugrel 5 mg MD in elderly patients who were poor responders to clopidogrel was associated with greater platelet inhibition
TRIGGER-PCI1952012212 stable patientsClopidogrel/prasugrel treated with DESIn patients who were poor responders to clopidogrel, prasugrel LD produced an antiplatelet effect with a good safety profile.
Lhermusier et al.196201280 ACS patientsClopidogrel/prasugrelIn patients who were poor responders to clopidogrel, prasugrel LD was associated with an effective antiplatelet effect.
Nuhrenberg et al.197201347 STEMI patientsClopidogrel/prasugrelPrasugrel LD produced optimal antiplatelet effect, independently of clopidogrel pre-loading.
Cuisset et al.1982013107 ACS patientsClopidogrel/prasugrelPrasugrel LD was associated with a better antiplatelet effect in diabetic patients with a fairly good safety profile (10% of major bleeding events).
TRIPLET1992013282 ACS patientsClopidogrel/prasugrelPlatelet reactivity obtained with prasugrel LD (60 mg) after 600 mg clopidogrel was not different from that obtained with prasugrel LD (60 mg) alone.

DES, drug-eluting stent; LD, loading dose; MD, maintenance dose; ACS, acute coronary syndrome; STEMI, ST elevation myocardial infarction.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close